MCRB Seres Therapeutics Inc.

+0.12  (+4%)
Previous Close 2.85
Open 2.84
Price To Book -11.42
Market Cap 207,642,828
Shares 69,913,410
Volume 265,762
Short Ratio
Av. Daily Volume 696,610

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due early 2020.
Recurrent C. Difficile infection
Phase 2b data due 3Q 2020.
Mild-to-Moderate Ulcerative Colitis
Phase 1b data due 2H 2020.

Latest News

  1. Edited Transcript of MCRB earnings conference call or presentation 6-Aug-19 12:00pm GMT
  2. Microbiome biotechs grapple with how to protect their IP
  3. Seres Therapeutics Inc (MCRB) Q2 2019 Earnings Call Transcript
  4. Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates
  5. Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
  6. Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
  7. Seres Therapeutics, Inc. to Host Earnings Call
  8. Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  9. Do Directors Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares?
  10. What Kind Of Shareholders Own Seres Therapeutics, Inc. (NASDAQ:MCRB)?
  11. Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
  12. Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
  13. Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
  14. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  15. Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  16. Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
  17. Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT
  18. Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
  19. Seres Therapeutics: 1Q Earnings Snapshot
  20. Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update